Pulmonary rehabilitation in patients diagnosed with non-IPF-fibrosing interstitial lung disease receiving antifibrotic therapy

<bold>Introduction:</bold> Pulmonary rehabilitation (PR) improves functional and psychosocial status in interstitial lung diseases (ILD). This study explored PR's efficacy in non-IPF fibrosing ILD patients on antifibrotics. <bold>Methods:</bold> Nineteen patients with non-IPF fibrosing ILD, receiving antifibrotics had an 8-week multidisciplinary, comprehensive, directly supervised PR. Patients' functional and clinic parameters, psychosocial status, and quality of life were analyzed. <bold>Results:</bold> Out of all patients, 5 were women, with an average age of 57.95. Nine patients were diagnosed with post-COVID fibrosis, 3 with chronic hypersensitivity pneumonia, 2 each with combined pulmonary fibrosis and emphysema and interstitial pneumonia with autoimmune features, and 1 each with lung involvement of systemic lupus erythematosus, systemic sclerosis, and fibrotic non-specific interstitial pneumonia. Eleven were on nintedanib, and eight were on pirfenidone. While most parameters improved post-PR, statistically significant gains were seen only in exercise capacity and peripheral muscle strength (Table 1). <bold>Discussion:</bold> In the multidisciplinary and comprehensive management of fibrosing ILD, PR can effectively identify and control treatable features. <table-wrap><object-id>erj;64/suppl_68/PA3187/TB1</object-id><object-id>T1</object-id><object-id>TB1</object-id><table><colgroup><col></col><col></col><col></col><col></col></colgroup><tbody><tr><td></td><td><bold>Pre-PR Mean±SD</bold></td><td><bold>Post-PR Mean±SD</bold></td><td><bold>p</bold></td></tr><tr><td><bold>BMI</bold></td><td>27.80±6.03</td><td>26.98±6.12</td><td>0. 701</td></tr><tr><td><bold>FFMI</bold></td><td>20.39±3.22</td><td>19.15±2.59</td><td>0.602</td></tr><tr><td><bold>FVC</bold></td><td>66.56±21.33</td><td>60.40±19.32</td><td>0.758</td></tr><tr><td><bold>FEV1</bold></td><td>65.19±15.39</td><td>65.00±16.72</td><td>0.297</td></tr><tr><td><bold>ISWT</bold></td><td>254.44±150.9</td><td>271.00±147.2</td><td><bold>0.025</bold></td></tr><tr><td> <bold>MIP/MEP</bold> </td><td>103.71±26.44/139.42±30.76</td><td>118.40±23.12/161.40±28.31</td><td>0.105/0.257</td></tr><tr><td><bold>Handgrip</bold></td><td>31.57±8.57</td><td>34.85±7.30</td><td><bold>0.008</bold></td></tr><tr><td><bold>HADS-A/ HADS-D</bold></td><td>4.61±3.69/4.06±3.29</td><td>3.50±2.75/3.50±2.96</td><td>0.052<bold>/</bold>0.217</td></tr><tr><td><bold>SGRQ</bold></td><td>49.01±23.21</td><td>38.95±22.36</td><td>0.052</td></tr></tbody></table></table-wrap>